All the news Showing 10 of 24 articles from: AASLD 2015Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Genotype 3 Daclatasvir and sofosbuvir with ribavirin cures 90% of people with genotype 3 hepatitis C Liz Highleyman / 24 November 2015 An all-oral combination of daclatasvir, sofosbuvir and ribavirin taken for 12 or 16 weeks led to high sustained virological response rates for people with hard-to-treat hepatitis C virus (HCV) genotype 3 and advanced ... Genotype 3 Daclatasvir plus sofosbuvir works well for people with genotype 3 hepatitis C and advanced liver disease in real-world clinical practice Liz Highleyman / 24 November 2015 Interferon-free treatment with daclatasvir plus sofosbuvir, with or without ribavirin, led to sustained virological response in a majority of people with genotype 3 hepatitis C virus (HCV) and advanced liver disease treated in ... Mother to child Tenofovir during pregnancy reduces risk of mother-to-child hepatitis B virus transmission Liz Highleyman / 23 November 2015 Women with chronic hepatitis B and high viral load who were treated with tenofovir (Viread) during pregnancy were significantly less likely to transmit hepatitis B virus (HBV) to their babies, according to study ... Treatment outcomes Liver fibrosis improves after successful treatment for hepatitis C Liz Highleyman / 23 November 2015 A majority of people with chronic hepatitis C and advanced fibrosis or cirrhosis showed improvement in liver health following treatment, according to study findings presented last week at the 2015 AASLD Liver ... Protease inhibitors Sofosbuvir/ledipasvir plus vedroprevir shows 96% response rate for hard-to-treat genotype 1 hepatitis C patients Liz Highleyman / 19 November 2015 A triple combination of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) plus the experimental HCV protease inhibitor vedroprevir cured 96% of treatment-experienced genotype 1 hepatitis C patients with cirrhosis, without the need for ribavirin, according to study ... Ns5A inhibitors Sofosbuvir/velpatasvir shows high cure rates for all HCV genotypes, works well for patients with liver decompensation Liz Highleyman / 18 November 2015 A co-formulation of sofosbuvir and the pan-genotypic HCV NS5A inhibitor velpatasvir from Gilead Sciences produced sustained response in 99% of people with hepatitis C virus genotypes 1, 2, 4, 5 and 6, ... Access to medicines & diagnostics Almost half of US Medicaid recipients denied funding for hepatitis C treatment, 4-state study shows Keith Alcorn / 17 November 2015 Around one in six people with hepatitis C in four US states had their prescriptions for direct-acting antivirals refused by insurers, and almost half of Medicaid recipients were denied reimbursement in 2014 ... Genotype 4 Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients Liz Highleyman / 17 November 2015 A regimen of sofosbuvir and the pan-genotypic HCV NS5A inhibitor ravidasvir, with or without ribavirin, demonstrated sustained response rates ranging from 86% to 100% in the largest phase 3 trial to ... Treatment for previous non-responders & relapsers Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment Keith Alcorn / 17 November 2015 Re-treating with an interferon-free regimen that previously failed to cure hepatitis C can result in success if treatment is intensified with the addition of sofosbuvir, two studies presented this week at the ... New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study Keith Alcorn / 16 November 2015 A combination of two experimental direct-acting antivirals developed by AbbVie cured 97 to 100% of people without cirrhosis with genotype 1 hepatitis C infection in a mid-stage phase 2 study presented this ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive